A game-changing delivery system for Long-Acting Injectables
BEPO® is a simple yet flexible technology. Based on our custom proprietary copolymers and a biocompatible solvent (where the API is solubilized or suspended), BEPO® forms a fully bioresorbable depot once injected. BEPO® can provide a controlled release of therapeutic molecules for days, weeks or months and therefore can be used to improve the treatment for a large variety of chronic diseases or short-term illnesses. BEPO® can be administered subcutaneously for systemic exposure of APIs or locally for targeted treatments.
BEPO® is composed of a solution of diblock (DB) and triblock (TB) copolymers containing hydrophilic and water-soluble blocks (polyethylene glycol – PEG) linked with hydrophobic and amorphous blocks (Poly(D,L-lactic acid) – PLA) which precipitate in forming a depot when exposed to an aqueous environment. The API is entrapped within the polymer matrix and is released thereafter by diffusion and following polymer degradation. The hygroscopy and consequently the API release kinetics from the depots can be fine tuned by adjusting the hydrophilicity of the DB and TB and their relative ratio.
• PEG (polyethylene glycol) block
• Also known as polyethylene oxide (PEO)
• Commercially available over a wide range of MW
• Hydrophilic, water soluble
• PLA block
• Poly (D,L-lactic acid) or poly (D,L-lactide)
• Prepared by polymerization
(ROP) of cyclic (D,L)-lactide monomer
• Amorphous, hydrophobic
• Biodegradable macromolecule
Diblock Copolymers (DB)
Triblock Copolymers (TB)
A flexible technology
The possibility of fine-tuning all of BEPOs components make it a truly tailorable product, able to fit the therapeutic needs of the patient.